Related Experiment Videos
The luteal phase after ovarian stimulation.
Efstratios M Kolibianakis1, Paul Devroey
1Centre for Reproductive Medicine, Dutch Speaking Brussels Free University, Belgium. ekolibia@az.vub.ac.be
Reproductive Biomedicine Online
|January 23, 2003
Summary
Luteal phase support after ovarian stimulation is complex. Progesterone supplementation is essential in GnRH agonist cycles but not proven effective in clomiphene citrate/human menopausal gonadotrophin cycles.
Area of Science:
- Reproductive endocrinology
- Assisted reproductive technology
Background:
- The luteal phase is critical for successful implantation following ovarian stimulation.
- Current evidence on luteal phase support varies depending on the stimulation protocol used.
Purpose of the Study:
- To evaluate the necessity and efficacy of luteal phase supplementation with progesterone across different ovarian stimulation protocols.
Main Methods:
- Review of existing literature and clinical practices regarding luteal phase support.
- Analysis of outcomes in cycles stimulated with clomiphene citrate/human menopausal gonadotrophins, GnRH agonists/gonadotrophins, and GnRH antagonists.
Main Results:
- Luteal supplementation with progesterone has not been proven to increase implantation rates in clomiphene citrate/human menopausal gonadotrophin cycles.
- Luteal phase support is considered essential for pregnancy achievement in GnRH agonist/gonadotrophin cycles.
- Randomized controlled trials are lacking to support luteal supplementation in GnRH antagonist cycles.
- Gonadotrophin stimulation with human chorionic gonadotrophin appears to result in an inadequate luteal phase, irrespective of agonist or antagonist use.
Conclusions:
- The requirement for luteal phase support varies significantly based on the ovarian stimulation protocol.
- Further research, particularly randomized controlled trials, is needed to clarify the role of progesterone supplementation in GnRH antagonist cycles.
- Optimizing luteal phase support remains crucial for improving pregnancy rates in assisted reproductive technology.